We report two cases of human herpesvirus-6 (HHV-6)-associated encephalitis in patients after BMT. Both patients reported distinct neurological symptoms with disorientation, sleepiness and loss of short-term memory. Diagnosis was based on PCR analysis of the cerebrospinal fluid (CSF) positive for HHV-6 variant B-DNA. After institution of therapy with foscarnet in both cases, neurological symptoms improved and in one patient clearance of HHV-6-DNA from CSF was demonstrated. These cases show that HHV-6 infection has to be considered in patients with neurological symptoms following BMT and effective treatment of HHV-6 encephalitis is possible if instituted early. Keywords: human herpesvirus-6; bone marrow transplantation; encephalitis; foscarnet Human herpesvirus-6 (HHV-6) is a member of the betaherpesvirus subfamily causing exanthem subitum in children.
Human herpesvirus-6 (HHV-6) is a member of the betaherpesvirus subfamily causing exanthem subitum in children. 1 Since its discovery in 1986, HHV-6 has been an emerging pathogen, especially in the immunocompromised host. In patients after BMT the reported incidence based on screening blood samples post transplant by polymerase chain reaction (PCR) is between 38-60%. 2 Infection occurs by reactivation of latent virus or exogenous infection. HHV-6 infection in transplant patients had been associated clinically with skin rash and fever, marrow suppression, interstitial pneumonitis and encephalitis. 1 Furthermore, there are reports that HHV-6 infection is associated with an increased incidence of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection 3 and the occurrence of graft-versus-host disease (GVHD). 4 To date, there are only three reports of HHV-6-associated encephalitis in patients after bone marrow transplantation in the literature and two proved to be fatal, demonstrating the potential morbidity and mortality of this infection. [5] [6] [7] As HHV-6 is susceptible to ganciclovir and foscarnet but less sensitive to acyclovir, 1 clinical disease caused by this virus is potentially treatable. Here, we report two cases of HHV-6 encephalitis after allogeneic BMT successfully treated with foscarnet.
Case reports

Patient 1
A 34-year-old man received an allogeneic unrelated BMT for relapsed acute lymphoblastic leukemia in January 1998. The conditioning regimen consisted of total body irradiation (12 Gy), etoposide 40 mg/kg and cyclophosphamide 120 mg/kg. GVHD prophylaxis consisted of antithymocyte globulin (ATG) (Thymoglobulin; Meriéux, Leimen, Germany) 3.5 mg/kg/day from day 4 (−4) before transplantation to day −1, cyclosporin A 5 mg/kg from day −1, prednisone 0.5 mg/kg from days +7 to 14, prednisone 1 mg/kg from days +14 to +28 and mycophenolate from day +0. The patient received ofloxacin, fluconazole and polyvalent immunoglobulin preparations every 3 weeks post BMT as antimicrobial prophylaxis. The recipient and donor were CMV seropositive. The patient was screened weekly by PCR for CMV-DNA. The early post-transplant period was without severe complications, in particular, no signs of GVHD. Two months after transplantation the patient developed CMV viremia and in spite of treatment with foscarnet this progressed to pneumonitis. Treatment was escalated with combined use of foscarnet and ganciclovir, broad-spectrum antibiotics and systemic amphotericin B. The patient subsequently improved and the pneumonitis resolved. One hundred days post transplantation he presented with fever, nausea, slight headaches and progressive retrograde amnesia. There was no history of fits, paralysis or other focal neurologic symptoms. He reported having a febrile episode with a generalized rash a week before admission. An MRI study of the brain showed no abnormality apart from focal signal abnormalities in the subcortical white matter; there were no signs of herpes encephalitis. A lumbar puncture was performed yielding mild pleocytosis with slight elevation of lactate, normal protein and glucose suggestive of viral meningoencephalitis. All cerebrospinal fluid and blood cultures for bacterial, fungal and viral organisms were negative as were serologic studies for herpes simplex virus (HSV), VZV, EBV and a variety of other viruses. CMV-and HHV-6-specific IgG and CMV-specific IgM were detectable in serum whereas assays for HHV-6-specific IgM were negative. PCR analysis of the CSF was positive for HHV-6-DNA ( Figure 1 ) but negative for HSV-, EBV-, CMV-, VZV-and JC-virus (JCV)-DNA. Furthermore, HHV-6-DNA could be detected in peripheral blood leukocytes, whereas PCR analysis of the plasma was negative. Restriction fragment analysis of the PCR product obtained from CSF allowed classification of the isolate as HHV-6-variant B. The patient was started on 3 × 60 mg/kg foscarnet. Neurological symptoms improved rapidly within 2 weeks and a second CSF examination 14 days after institution of antiviral therapy was negative for HHV-6-DNA by PCR. After 3 weeks of therapy with foscarnet the patient was discharged with neurological disturbances completely resolved.
Patient 2
A 54-year-old woman received an allogeneic BMT from an HLA-identical sibling in March 1995 for chronic myeloid leukemia. Conditioning was with busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. GVHD prophylaxis consisted of cyclosporin A 5 mg/kg from dayϪ1 and methotrexate 15 mg/m 2 on day +1, respectively, 10 mg/m 2 on days +3 and +6. For antimicrobial prophylaxis she received ofloxacin, fluconazole and polyvalent immunoglobulin preparations every 3 weeks post BMT. The recipient was CMV-seropositive and was screened weekly by PCR for CMV-DNA in blood samples. After isolation of HSV by cell culture from throat washings acyclovir (3 × 5 mg/kg) was started. Grade II GVHD developed on day +10 with skin rash and fever; symptoms rapidly improved when corticosteroids (1 mg/kg) were started but on day +15 fever recurred. Chest X-ray showed a pulmonary lesion, highly suspicious of invasive pulmonary aspergillosis. Broad-spectrum antibiotics and amphotericin B (1 mg/kg) were started and after an initial response her temperature rose again on day +23 up to 39°C. In addition, the patient complained of Detection of HHV-6-DNA in peripheral blood leukocytes (7) but not in plasma (6) . Note that PCR product derived from pVGUdel is 60 bp smaller in size as compared to clinical isolates.
headaches, tremor, nystagmus and ataxia. Magnetic resonance imaging (MRI) showed slight signal abnormalities in the left cerebellum, suspicious of cerebellar ischemia or drug toxicity, and cyclosporin A was stopped. Because of fever, diarrhoea and a rise in bilirubin (2.5 mg/dl) typical for GVHD the dose of corticosteroids was increased to 2 mg/kg per day. Again, the fever and clinical condition of the patient improved. Two weeks later the patient complained of profound sleepiness, progressive loss of shortterm memory and disorientation without focal neurological symptoms. Over the following days her neurological situation deteriorated further with progressive loss of consciousness. A MRI study showed bilateral foci of signal abnormalities in the region of the hippocampus suggesting viral encephalitis (Figure 2) . A lumbar puncture was performed yielding mild pleocytosis but normal levels for protein, lactate and glucose. PCR analysis of cerebrospinal fluid (CSF) showed negative results for CMV-, EBV-, HSV-and JCV-DNA but was positive for HHV-6-DNA. Restriction fragment analysis of the PCR product obtained from CSF classified the isolate as HHV-6-variant B. All cerebrospinal fluid and blood cultures for bacterial, fungal and viral organisms were negative. IgG specific for CMV and HHV-6 was detectable in serum, whereas assays for the detection of CMV-specific IgM and HHV-6-specific IgM were negative. Serological studies for a variety of other viruses were negative. PCR analysis for HHV-6-DNA in serum samples were negative throughout her illness. Treatment with 3 × 60 mg/kg foscarnet was initiated and the neurological symptoms improved with full recovery of consciousness, orientation and short-term memory after 2 weeks. Foscarnet was continued for a total of 3 weeks. Subsequently, the patient developed increasingly severe GVHD of bowel and liver resistant to intensive immunosuppressive treatment. She finally died of bowel GVHD with severe bleeding. Autopsy was refused. 
Discussion
HHV-6 is an increasingly recognized pathogen in the immunocompromised patient. The two cases reported here demonstrate the potential role of HHV-6 in central nervous system infections in patients after BMT. Humans are the primary host for the known eight members of the herpes virus family. The HHV-6 entity consists of two closely related but distinct viruses named human herpes virus-6 variant A (HHV-6A) and B (HHV-6B). Infection normally occurs in early childhood by close contact or respiratory transmission resulting in a rate of seropositivity of over 95% in people older than 2 years. So far HHV-6A has rarely been found to cause any clinically relevant disease whereas HHV-6B is the etiologic agent of exanthem subitum, related febrile illnesses and is increasingly described as a pathogen in the immunocompromised host. 1 In patients after BMT an incidence of 38-60% for HHV-6 infection, predominantly variant B, is described by PCR analysis. 2 In these patients an association of HHV-6 infection with interstitial pneumonitis, marrow suppression, acute GVHD and fatal encephalitis has been found. 1 
As well as in CD4
+ T cells, HHV-6 has been found in lymph nodes, in salivary glands, lymphocytes, macrophages, monocytes and kidney tubule endothelial cells. 1 In the CNS, viral gene products have been demonstrated in neurons, astrocytes 5 and oligodendrocytes. 8 CNS disease caused by HHV-6 is described in immunocompetent as well as in immunocompromised patients. In children with exanthem subitum febrile seizures, distention of the anterior fontanelle, hemiplegia and meningoencephalitis are described suggesting direct invasion of the CNS during primary infection. There are also reports of fulminant encephalitis caused by HHV-6 in immunocompromised patients with AIDS. 9 In patients after BMT there have been three reports of HHV-6-associated encephalitis to date, and two proved to be fatal. [5] [6] [7] We describe two further cases of HHV-6-associated encephalitis in BMT patients (Table 1) . Both patients developed characteristic neurological symptoms, namely loss of short-term memory, headaches, sleepiness and disorientation. These symptoms were most likely due to invasion of the limbic system by HHV-6 as described for other herpesviruses. In patient 2 correspondant signal Table 1 Summary and comparison of the essential facts of the two patients abnormalities in the hippocampal region could be demonstrated on MRI scan (Figure 2 ). There are also reports of white matter demyelination caused by HHV-6, producing lesions similar to multiple sclerosis 10 or progressive multifocal leukoencephalopathy as found in patient 2. The skin rash reported by patient 1 one week before admission might also be attributed to HHV-6, since in 33% of HHV-6 infected patients after BMT a skin rash and fever was present in one study.
11 Diagnosis in our patients was based on PCR analysis of CSF. As PCR also detected HHV-6 DNA in peripheral blood lymphocytes of patient 1, one might argue the PCR assay used detected latent HHV-6 DNA of lymphocytes found in the CSF. However, detection of HHV-6 DNA in peripheral blood lymphocytes is done by analysis of large numbers of lymphocytes and special separation techniques not used in our PCR assay from CSF. PCR analysis of the CSF has been described as the first-line diagnostic test for patients with herpes-simplex-encephalitis superior to brain biopsy. 12 Furthermore, 14 days after initiating treatment with foscarnet in this patient, HHV-6 DNA was no longer detectable in the CSF. Both patients were positive for HHV-6-specific IgG before onset of neurological symptoms suggesting reactivation of the virus. The failure to develop HHV-6-specific IgM could be explained by reactivation of latent virus and/or the post-transplant setting with a severely impaired immune response.
HHV-6 has been tested for susceptibility to various antiviral agents in vitro. The data indicate greater susceptibility of HHV-6 to ganciclovir and foscarnet than to acyclovir. The susceptibility of variant A strains to ganciclovir varies in different reports with relative resistance in some. 1 Foscarnet might be preferable to ganciclovir if the HHV-6 variant and susceptibility are not known. In addition, foscarnet is found in higher concentrations in the CSF than ganciclovir.
Clinical experience with the treatment of HHV-6-associated encephalitis in BMT patients is limited. There is only one report of successful treatment with ganciclovir so far in the literature. 6 We report the successful treatment of two cases of encephalitis in this setting by foscarnet. As early treatment is vital for a successful outcome, institution of antiviral treatment should occur on an empirical basis before diagnostic test results are available, as happened in these cases. The high seroprevalence in the general popu-lation and potential mortality and morbidity caused in posttransplant patients makes routine surveillance of these patients an issue. Weekly assessment of blood samples by PCR for HHV-6 could be recommended in the first 3 months after transplantation, allowing early institution of treatment if the criteria proposed by Singh and Carrigan 2 are met.
In summary, we describe two patients after BMT suffering from HHV-6-associated encephalitis successfully treated by foscarnet. HHV-6 infection should be considered in patients with neurological symptoms following BMT and early institution of antiviral treatment is mandatory. Further research into the role of HHV-6 as a pathogen in transplant patients and adequate prophylactic or therapeutic treatment should be undertaken.
